Oppenheimer analyst Leland Gershell assigned a Buy rating to Corbus Pharmaceuticals (CRBP) yesterday and set a price target of $28.00. The company’s shares closed last Monday at $6.64.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 11.1% and a 52.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Miragen Therapeutics.
Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $26.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.81 and a one-year low of $3.29. Currently, Corbus Pharmaceuticals has an average volume of 1.02M.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
